




APPENDIX 4C – 4TH QUARTER FY18/19 QUARTERLY REPORT

Resonance Health Limited (ASX: RHT) (“Resonance Health” or “Company”) today releases its Appendix 4C – Quarterly Report for the period ended 30 June 2019.

Summary of Key Financials and Business Performance

- Cash receipts from customers for the June 2019 quarter were \$991K, a new high for the Company, and an increase of 15% versus the June quarter for the previous year.
- Total revenue for the June quarter was \$886K (unaudited), an increase of 13% versus the June quarter for the previous year.
- Cash on hand as of 30 June 2019 was \$3.08m, an increase of \$613K over the March 2019 quarter. The June quarter included \$250K cash received in relation to 4.5 million shares issued on conversion of the unlisted option with fully paid shares.



+Rule 4.7B

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

Resonance Health Limited	
<b>ABN</b>	<b>Quarter ended (“current quarter”)</b>
96 006 762 492	30 June 2019

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A’000</b>	<b>Year to date (12months) \$A’000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	991	3539
1.2 Payments for		
(a) research and development	(80)	(506)
(b) product manufacturing and operating costs		
(c) advertising and marketing	(67)	(267)
(d) leased assets		
(e) staff costs	(405)	(1456)
(f) administration and corporate costs	(76)	(389)
1.3 Dividends received (see note 3)		
1.4 Interest received	4	21
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives	0	328
<b>1.9 Net cash from / (used in) operating activities</b>	<b>367</b>	<b>1270</b>

+ See chapter 19 for defined terms.

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (12months) \$A'000</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	(0)	(3)
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.2 Proceeds from disposal of:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
<b>2.6 Net cash from / (used in) investing activities</b>	<b>(0)</b>	<b>(3)</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares		
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options	250	250
3.4 Transaction costs related to issues of shares, convertible notes or options		
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		

+ See chapter 19 for defined terms.

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (12months) \$A'000</b>
3.8 Dividends paid		
3.9 Other (provide details if material)		
<b>3.10 Net cash from / (used in) financing activities</b>	<b>250*</b>	<b>250*</b>

\* Payment received in June 2019 in relation to 4.5 million shares issued on conversion of the unlisted options with fully –paid ordinary shares (Appendix 3B announced on 16 Jul 19)

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	2468	1549
4.2 Net cash from / (used in) operating activities (item 1.9 above)	367	1270
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(0)	(3)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	250	250
4.5 Effect of movement in exchange rates on cash held	(4)	15
<b>4.6 Cash and cash equivalents at end of quarter</b>	<b>3081</b>	<b>3081</b>

<b>5. Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter</b> <b>\$A'000</b>	<b>Previous quarter</b> <b>\$A'000</b>
5.1 Bank balances	3081	2468
5.2 Call deposits		
5.3 Bank overdrafts		
5.4 Other (provide details)		
<b>5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>3081</b>	<b>2468</b>

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

**Current quarter**  
**\$A'000**

60

\$45K – Directors fees  
\$15K – Consultancy fees

<b>7.</b>	<b>Payments to related entities of the entity and their associates</b>	<b>Current quarter \$A'000</b>
7.1	Aggregate amount of payments to these parties included in item 1.2	
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

<b>8.</b>	<b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
8.1	Loan facilities		
8.2	Credit standby arrangements		
8.3	Other (please specify)		
8.4	Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

+ See chapter 19 for defined terms.

<b>9.</b>	<b>Estimated cash outflows for next quarter</b>	<b>\$A'000</b>
9.1	Research and development	(180)
9.2	Product manufacturing and operating costs	-
9.3	Advertising and marketing	(68)
9.4	Leased assets	-
9.5	Staff costs	(350)
9.6	Administration and corporate costs	(82)
	<b>Estimated cash outflows</b>	<b>(680)</b>
9.7	Estimated receivables	750
<b>9.8</b>	<b>Total estimated cash inflows</b>	<b>70</b>

<b>10.</b>	<b>Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	<b>Acquisitions</b>	<b>Disposals</b>
10.1	Name of entity		
10.2	Place of incorporation or registration		
10.3	Consideration for acquisition or disposal		
10.4	Total net assets		
10.5	Nature of business		

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: **Agha Shahzad Pervez**  
(Company secretary)

Date: 29 July 2019

## Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows*

apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.